Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mometasone furoate nasal spray is a synthetic corticosteroid used intranasally to treat and prevent symptoms of allergic rhinitis (seasonal and perennial) and to treat nasal polyps. It works by reducing inflammation through multiple mechanisms, including inhibition of inflammatory cell migration, suppression of mediator release (such as histamine), stabilization of cell membranes, and reduction in capillary permeability. When used in combination with an oral antibiotic—most commonly amoxicillin/clavulanate—it serves as adjunctive therapy for acute or recurrent rhinosinusitis. Clinical studies have shown that adding mometasone furoate nasal spray to antibiotics improves symptom relief compared to antibiotics alone[3][4][5]. The primary indication for this combination is moderate-to-severe acute or recurrent rhinosinusitis confirmed by clinical or imaging criteria.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mometasone furoate nasal spray + antibiotic.